CytomX Therapeutics, Inc.
CTMX
$3.36
$0.010.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -13.25% | 31.17% | -86.31% | -9,139.61% | -100.65% |
| Total Depreciation and Amortization | -81.27% | -50.78% | 280.60% | -61.38% | -9.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.82% | 120.06% | 23.50% | -12.18% | -18.71% |
| Change in Net Operating Assets | 100.29% | -3,017.97% | 113.02% | 81.57% | 61.99% |
| Cash from Operations | 29.28% | -9.92% | -49.49% | 1.30% | 25.14% |
| Capital Expenditure | -- | -- | -258.27% | 570.37% | 77.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 103.09% | -1,255.87% | -4,657.05% | 100.41% | -348.52% |
| Cash from Investing | 103.09% | -1,236.97% | -3,384.51% | 100.57% | -349.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.78% | 1,273.74% | 6,478.26% | -99.73% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -- | -- | -- |
| Cash from Financing | -99.78% | 1,308.92% | 6,478.26% | -99.73% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -171.80% | 176.89% | -41.48% | -1,133.82% | -84.96% |